Form 483

Optimal Solution Labs LLC Form 483, 2024-11-06

FDA issued a Form 483 to Optimal Solution Labs LLC on 2024-11-06 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

Optimal Solution Labs LLC · Valencia, United States · Issued November 6, 2024

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

6 Nov 2024
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Tiara M Brown

6 Nov 2024
21 CFR 211.122(d)

Label storage access limited to authorized personnel

Cited by Tiara M Brown

6 Nov 2024
21 CFR 211.166(a)

Lack of written stability program

Cited by Tiara M Brown

6 Nov 2024
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Tiara M Brown

6 Nov 2024
21 CFR 211.63

Equipment Design, Size and Location

Cited by Tiara M Brown

Inspected site

OSOptimal Solution Labs LLCValencia, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.122(d)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x
21 CFR 211.67(c)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere